Genomic strategies determining progression from MGUS to multiple myeloma

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In the past years we have learned much about the genetics and biology of multiple myeloma (MM) and plasma cell disorders. It is now clear that (nearly) all MM cases are preceded by a benign phase of expansion of monoclonal PCs known as monoclonal gammopathy of undetermined signi fi cance (MGUS). It is also known that MGUS is a common condition that increases in prevalence with advancing age. Trying to couple the understanding we have of the genetics of the disease with the speci fi c risk of progression from MGUS to MM could be of importance in determining different risk of progression with associated management strategies. Currently there is limited information regarding the speci fi c factors that drive the progression from MGUS to MM and the risk associated with different genetics classes of the disease. A better understanding of the biologic steps that are needed for progression from a benign stage to a malignant form of the disease is needed, as well as better markers to provide a more dynamic monitoring for incipient disease evolution. In this chapter we discuss some of the background knowledge and basic biology of the disease, and some future strategies for a better surveillance of patients with MGUS.

Original languageEnglish (US)
Title of host publicationAdvances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science
PublisherSpringer New York
Pages3-24
Number of pages22
ISBN (Print)9781461446668, 9781461446651
DOIs
StatePublished - Jan 1 2013

Fingerprint

Paraproteinemias
Multiple Myeloma
Inborn Genetic Diseases
Naphazoline
Plasma Cells

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Braggio, E. D., & Fonseca, R. (2013). Genomic strategies determining progression from MGUS to multiple myeloma. In Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science (pp. 3-24). Springer New York. https://doi.org/10.1007/978-1-4614-4666-8_1

Genomic strategies determining progression from MGUS to multiple myeloma. / Braggio, Esteban D; Fonseca, Rafael.

Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York, 2013. p. 3-24.

Research output: Chapter in Book/Report/Conference proceedingChapter

Braggio, ED & Fonseca, R 2013, Genomic strategies determining progression from MGUS to multiple myeloma. in Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York, pp. 3-24. https://doi.org/10.1007/978-1-4614-4666-8_1
Braggio ED, Fonseca R. Genomic strategies determining progression from MGUS to multiple myeloma. In Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York. 2013. p. 3-24 https://doi.org/10.1007/978-1-4614-4666-8_1
Braggio, Esteban D ; Fonseca, Rafael. / Genomic strategies determining progression from MGUS to multiple myeloma. Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science. Springer New York, 2013. pp. 3-24
@inbook{70b707236be94ef890215ee34eb3ee90,
title = "Genomic strategies determining progression from MGUS to multiple myeloma",
abstract = "In the past years we have learned much about the genetics and biology of multiple myeloma (MM) and plasma cell disorders. It is now clear that (nearly) all MM cases are preceded by a benign phase of expansion of monoclonal PCs known as monoclonal gammopathy of undetermined signi fi cance (MGUS). It is also known that MGUS is a common condition that increases in prevalence with advancing age. Trying to couple the understanding we have of the genetics of the disease with the speci fi c risk of progression from MGUS to MM could be of importance in determining different risk of progression with associated management strategies. Currently there is limited information regarding the speci fi c factors that drive the progression from MGUS to MM and the risk associated with different genetics classes of the disease. A better understanding of the biologic steps that are needed for progression from a benign stage to a malignant form of the disease is needed, as well as better markers to provide a more dynamic monitoring for incipient disease evolution. In this chapter we discuss some of the background knowledge and basic biology of the disease, and some future strategies for a better surveillance of patients with MGUS.",
author = "Braggio, {Esteban D} and Rafael Fonseca",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-4666-8_1",
language = "English (US)",
isbn = "9781461446668",
pages = "3--24",
booktitle = "Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science",
publisher = "Springer New York",

}

TY - CHAP

T1 - Genomic strategies determining progression from MGUS to multiple myeloma

AU - Braggio, Esteban D

AU - Fonseca, Rafael

PY - 2013/1/1

Y1 - 2013/1/1

N2 - In the past years we have learned much about the genetics and biology of multiple myeloma (MM) and plasma cell disorders. It is now clear that (nearly) all MM cases are preceded by a benign phase of expansion of monoclonal PCs known as monoclonal gammopathy of undetermined signi fi cance (MGUS). It is also known that MGUS is a common condition that increases in prevalence with advancing age. Trying to couple the understanding we have of the genetics of the disease with the speci fi c risk of progression from MGUS to MM could be of importance in determining different risk of progression with associated management strategies. Currently there is limited information regarding the speci fi c factors that drive the progression from MGUS to MM and the risk associated with different genetics classes of the disease. A better understanding of the biologic steps that are needed for progression from a benign stage to a malignant form of the disease is needed, as well as better markers to provide a more dynamic monitoring for incipient disease evolution. In this chapter we discuss some of the background knowledge and basic biology of the disease, and some future strategies for a better surveillance of patients with MGUS.

AB - In the past years we have learned much about the genetics and biology of multiple myeloma (MM) and plasma cell disorders. It is now clear that (nearly) all MM cases are preceded by a benign phase of expansion of monoclonal PCs known as monoclonal gammopathy of undetermined signi fi cance (MGUS). It is also known that MGUS is a common condition that increases in prevalence with advancing age. Trying to couple the understanding we have of the genetics of the disease with the speci fi c risk of progression from MGUS to MM could be of importance in determining different risk of progression with associated management strategies. Currently there is limited information regarding the speci fi c factors that drive the progression from MGUS to MM and the risk associated with different genetics classes of the disease. A better understanding of the biologic steps that are needed for progression from a benign stage to a malignant form of the disease is needed, as well as better markers to provide a more dynamic monitoring for incipient disease evolution. In this chapter we discuss some of the background knowledge and basic biology of the disease, and some future strategies for a better surveillance of patients with MGUS.

UR - http://www.scopus.com/inward/record.url?scp=84948150134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948150134&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-4666-8_1

DO - 10.1007/978-1-4614-4666-8_1

M3 - Chapter

AN - SCOPUS:84948150134

SN - 9781461446668

SN - 9781461446651

SP - 3

EP - 24

BT - Advances in Biology and Therapy of Multiple Myeloma: Volume 1: Basic Science

PB - Springer New York

ER -